Gilead Sciences Inc. (GILD)

NASDAQ: GILD · USD

$159

+0.02 (+0.0%)· Recorded snapshot

Repli en anglaisFR

Affichage de la source anglaise pendant la traduction

Ce rapport n'a pas encore été traduit. Actualisez dans quelques minutes une fois que la file d'attente de traduction aura rattrapé son retard.

StockMarketAgent Research · Analyzed 2026-09-09

Our latest published analysis: GILD rated Hold

Gilead Sciences Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$140 / share

Potential value

$273 / share

Upside to FV

-4.8%

from $159

Moat

1/10

None

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$187.2B
Revenue (ttm)	30.5B
Net income (ttm)	-3.2B
EPS (ttm)	-$2.61
Shares out	1.2B
P/E (forward)	15.4x
Dividend	$3.28 (2.06%)
Volume	3,614,506
Beta	0.33

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 30.5B
Net income (ttm): -3.2B
EPS (ttm): -$2.61
P/E (forward): 15.4x
Market cap: $187.2B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$27.31B	$27.28B	$27.12B	$28.75B	$29.44B	+1.9%
Gross profit	$20.70B	$21.62B	$27.12B	$22.50B	$23.21B	+2.9%
Operating income	$9.92B	$7.33B	$7.61B	$1.66B	$10.02B	+0.3%
Net income	$6.23B	$4.59B	$5.67B	$480.0M	$8.51B	+8.1%
EPS (diluted)	$4.93	$3.64	$4.50	$0.38	$6.78	+8.3%
EBITDA	$11.33B	$8.85B	$7.61B	$4.43B	$13.58B	+4.6%
R&D	$4.60B	$4.98B	$5.72B	$5.91B	$5.80B	+6.0%
SG&A	$5.25B	$5.67B	$6.09B	$6.09B	$5.77B	+2.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	Vendre
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Réduire
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	Conserver
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Réduire
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	Achat fort
AMGN	Amgen Inc.	244.2B	28.1x	6.4x	19.8%	+8.4%	+58.6%	Acheter

Base and Bull scenarios

Base60%

Price target

$139.59

-4.8% from spot

FY2027 analyst consensus estimates support higher revenue and adjusted earnings. Growth then slows because HIV concentration limits the evidence for a longer expansion.

FY2027 revenue and adjusted EPS meet analyst consensus estimates.
Growth fades after FY2027 rather than continuing to accelerate.

Bull20%

Price target

$273.40

+86.4% from spot

Improvement beyond FY2027 requires a larger non-HIV contribution and strong free cash flow. These are scenario conditions, while the cited evidence records FY2025 levels. Lower cell-therapy sales or weaker free cash flow would disconfirm this path.

A larger non-HIV contribution is required; FY2025 cell-therapy sales establish a starting level, not future growth.
Free cash flow would need to remain strong relative to the FY2025 reported level.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($139.59). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
4.9%	$166	$180	$199	$228	$276
5.9%	$143	$151	$160	$174	$192
6.9%	$128	$133	$140	$146	$155
7.9%	$117	$120	$124	$129	$134
8.9%	$109	$111	$114	$117	$121

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E15.4

P25 n/aP50 n/aP75 n/a

Trailing P/E18.4

P25 n/aP50 n/aP75 n/a

ROE-20.7

P25 n/aP50 n/aP75 n/a

ROIC34.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GILD indicators

Market & fundamental data

Available fields

269

Groups with data

Currency

USD

Showing 269 of 269 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000882095
Company name	Gilead Sciences, Inc.
Country	United States
Country code	US
CUSIP number	375558103
Earnings date	2026-10-29
Earnings time	amc
Employees	17,000
Employees change	-600
Employees growth	-3.41%
Enterprise value	$218.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1987
In index	SP500, NASDAQ100
Industry	Drug Manufacturers - General
IPO date	1992-01-22
Is primary listing	Yes
Is SPAC	No
ISIN number	US3755581036
Last 10-K release date	2026-02-24
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	2013-01-28
Last stock split type	Forward
Market cap	$197.3B
Market cap category	Large-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$159.10
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	GILD
U.S. state	California
Website	https://www.gilead.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	75.16x
Average P/E ratio (3Y)	133.64x
Average P/E ratio (5Y)	84.97x
Earnings yield	-1.64%
EV/EBIT	18.53x
EV/EBITDA	15.03x
EV/FCF	16.95x
EV/Sales	7.2x
FCF / EV yield	5.9%
FCF yield	6.54%
Forward EV/Sales	6.94x
Forward P/E	18.03x
Forward P/S	6.27x
Industry forward P/E	18.59x
Industry P/E	36.43x
P/(FCF - SBC) ratio	16.46x
P/(OCF - SBC) ratio	15.66x
P/B ratio	16.69x
P/FCF ratio	15.3x
P/OCF ratio	14.61x
P/S ratio	6.5x
PEG ratio	2.58x
Price/EBITDA ratio	13.56x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	38.88%
EBITDA margin	47.94%
FCF margin	42.5%
Gross margin	79.6%
Operating margin	38.88%
Pretax margin	-6.42%
Profit margin	-10.64%
Profit per employee	$-190,588
Profitable years	19
Revenue per employee	$1.8M
ROA	14.09%
ROA (5Y)	10.85%
ROCE	30.88%
ROE	-20.68%
ROE (5Y)	24.33%
ROIC	34.37%
ROIC (5Y)	21.93%
SBC / revenue	2.98%
Tax / revenue	4.22%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
FCF growth	38.15%
FCF growth (Q)	376.81%
FCF growth (QoQ)	41.45%
FCF growth 3Y	13.19%
FCF growth 5Y	8.85%
Gross profit growth	6.96%
Gross profit growth (Q)	11.52%
Gross profit growth 3Y	3.69%
Gross profit growth 5Y	1.75%
Net income growth years	1
OCF growth	37.33%
OCF growth (Q)	332.04%
OCF growth (QoQ)	40.45%
OCF growth 10Y	-2.84%
OCF growth 3Y	12.52%
OCF growth 5Y	8.31%
Operating income growth	7.34%
Operating income growth (Q)	-5.23%
Operating income growth 3Y	6.62%
Operating income growth 5Y	-1.1%
Revenue growth	5.52%
Revenue growth (Q)	10.18%
Revenue growth (QoQ)	12.11%
Revenue growth 10Y	-0.61%
Revenue growth 3Y	3.61%
Revenue growth 5Y	2.72%
Revenue growth quarters	5
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-609M
Depreciation and amortization	$2.8B
EBIT	$11.8B
EBITDA	$14.6B
EPS	$-2.61
FCF per share	$10.44
Financing cash flow	$-4.6B
Free cash flow	$12.9B
Free cash flow minus SBC	$12B
Gross profit	$24.2B
Income taxes	$1.3B
Investing cash flow	$-10.8B
Net borrowing	$1.3B
Net cash flow	$-2B
Net income	$-3.2B
Operating cash flow minus SBC	$12.6B
Operating income	$11.8B
Revenue	$30.5B
Stock-based compensation	$909M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.05
Book value per share	$9.53
Debt / EBITDA	1.78
Debt / equity	2.23
Debt / FCF	2.03
Goodwill	$8.3B
Interest coverage	11.86
Long-term assets	$35.4B
Long-term liabilities	$26.6B
Net cash (debt)	$-21.4B
Net cash / market cap	-10.79%
Net debt / EBITDA	1.46
Net debt / equity	1.82
Net debt / FCF	1.65
Piotroski F-Score	5
Property, plant and equipment	$5.8B
Shareholders' equity	$11.7B
Tangible book value	$-10.5B
Tangible book value per share	$-8.47
Total assets	$49.4B
Total cash	$4.9B
Total debt	$26.2B
Total liabilities	$37.6B
WACC	5.72%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.58
Current assets	$13.9B
Current liabilities	$11B
Current ratio	1.27
Inventory turnover	3.29
Net working capital	$457M
Quick ratio	0.9
Working capital	$2.9B
Working capital turnover	9.44

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.39%
Dividend growth	3.5%
Dividend growth (10Y)	6.09%
Dividend growth (3Y)	2.93%
Dividend growth (5Y)	2.95%
Dividend growth years	10
Dividend payment date	2026-09-29
Dividend payment years	12
Dividend payout frequency	Quarterly
Dividend per share	$3.28
Dividend yield	2.06%
Ex-dividend date	2026-09-15
FCF payout ratio	31.42%
Last dividend	$0.82
Shareholder yield	3.44%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	109.81%
10Y return CAGR	11.57%
10Y total return	198.85%
150-day SMA	$138.27
15Y price change	655.64%
15Y return CAGR	17.39%
15Y total return	1,007.21%
1D price change	0.01%
1M price change	5.41%
1M total return	5.41%
1W price change	3.6%
1W total return	3.6%
1Y price change	32.07%
1Y return CAGR	35.36%
1Y total return	35.33%
20-day SMA	$152.25
200-day SMA	$139.43
20Y price change	833.41%
20Y return CAGR	13.97%
20Y total return	1,267.69%
3M price change	21.9%
3M total return	22.58%
3Y price change	107.65%
3Y return CAGR	31.65%
3Y total return	128.23%
50-day SMA	$149.97
50-day SMA vs 200-day SMA	50over200
52-week high	$160.83
52-week high date	2026-10-28
52-week low	$114.02
52-week low date	2025-10-31
5Y price change	138.28%
5Y return CAGR	23.28%
5Y total return	184.73%
6M price change	24.54%
6M total return	26.07%
All-time high	$160.83
All-time high date	2026-10-28
All-time low	$0.21
All-time low date	1994-06-08
Average true range (ATR)	$3.86
Average volume	5.7M
Beta (1Y)	0.11
Beta (2Y)	0.32
Beta (5Y)	0.33
Change from 52-week high	-1.08%
Change from 52-week low	39.54%
Change from all-time high	-1.08%
Change from all-time low	76,759.9%
Change from open	1.82%
Day's gap	-1.78%
Dollar volume	$575.1M
High price	$160.76
Low price	$156.25
Monthly RSI	72.52
Open price	$156.25
Position in 52-week range	63.19%
Premarket change	-0.66%
Premarket close	$159.08
Premarket price	$158.03
Premarket volume	2.5K
Previous close	$159.08
Price vs 150-day SMA	15.07%
Price vs 20-day SMA	4.5%
Price vs 200-day SMA	14.11%
Price vs 50-day SMA	6.09%
Relative volume	0.64
RSI	62.4
Sharpe ratio	1.12
Sharpe ratio (3Y)	1.01
Sharpe ratio (5Y)	0.8
Sortino ratio	2.03
Sortino ratio (3Y)	1.79
Sortino ratio (5Y)	1.51
Volume	3.6M
Weekly RSI	66.29
YTD price change	29.62%
YTD total return	31.96%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.2B
Float percentage	99.79%
Shares change (QoQ)	-0.88%
Shares change (YoY)	-1.39%
Shares held by insiders	0.09%
Shares held by institutions	90.91%
Shares outstanding	1.2B
Short % of float	1.76%
Short % of shares	1.76%
Short ratio	3.7 days

Deeper analysis on GILD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this GILD report

What is the latest published GILD stock rating?

Gilead Sciences Inc. is shown with Hold in the latest published report, analyzed 2026-09-09. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GILD analysis?

The full latest published report, analyzed 2026-09-09, lives at /stocks/GILD/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for GILD?

The latest published report analyzed 2026-09-09 gives GILD a fair value of USD 140 and a potential value of USD 273. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the GILD page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-09). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldGILD · Fair value $140-4.8%

Read full analysis →

Gilead Sciences Inc. (GILD)

Our latest published analysis: GILD rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · GILD

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All GILD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on GILD

Frequently asked questions

Historique des notations

Category	Score	Reading
Valuation	4.5
Management	6.5
Balance Sheet	3.5
Profitability	1.5
Revenue Growth	6.0
Risk Assessment	5.0
Competitive Moat	1.0
Earnings Quality	7.5
Capital Efficiency	7.5